Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PLRX

STRONG SELL

Pliant Therapeutics, Inc. · Healthcare · United States · $67M · Avg Vol: $642K/d

18
StockRank
Get insider-trade alerts
Q
28
V
36
M
38
P/E (TTM)
—
ROE
-53.6%
D/E
0.2x
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
None →
Loading 1Y...
PRICE (1Y)-4.4%
1.071.101.131.161.19Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$1.08
RSI (14)
37.1
52W High
$1.95
From 52W High
0.6%

SCORE BREAKDOWN

Quality
28
ROIC
-53.4%14.2
ROE
-53.6%17.2
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-57.1%4.5
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
0.17x53.5
Current Ratio
16.89x93.6
Value
36
P/E (TTM)
—N/A
EV/EBITDA
0.7x25.0
P/FCF
—N/A
P/B
0.4x98.4
P/S
—N/A
Div Yield
—N/A
Momentum
38
52W High %
55%33.1
RS 6M
-25%38.2
SMA 50/200
0.88x36.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+56%57.9
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$67M
P/E (Forward)
-1.3x
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLRX are excluded.

TickerCompanyMkt CapStockRankSignal
PLRXPliant Therapeutics, Inc.(you)$67M18STRONG SELL
4875.TMediciNova, Inc.$62M18STRONG SELL
OSTXOS Therapies Incorporated$68M16STRONG SELL
ACRVAcrivon Therapeutics, Inc.$68M14STRONG SELL
ACETAdicet Bio, Inc.$73M21SELL
VRCAVerrica Pharmaceuticals Inc.$86M16STRONG SELL
PMVPPMV Pharmaceuticals, Inc.$66M25SELL
FLNAFilana Therapeutics, Inc.$58M13STRONG SELL
IMAImageneBio, Inc.$63M11STRONG SELL
MAIAMAIA Biotechnology, Inc.$75M12STRONG SELL

Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%

Pliant Therapeutics, Inc. (PLRX) — Stock Score Summary

Pliant Therapeutics, Inc. (PLRX) has a MoatMap StockRank of 18/100 based on Quality (28/100), Value (36/100), and Momentum (38/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price$1.08
Market Cap$67M
P/E (Forward)-1.35
Price/Book0.41
Return on Equity-53.6%
Return on Invested Capital-53.4%
Debt/Equity0.17x
Operating Margin0.0%
Free Cash Flow$-129M

Pliant Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Pliant Therapeutics, Inc.’s (PLRX) StockRank?
MoatMap’s StockRank for Pliant Therapeutics, Inc. (PLRX) is 18/100, with a Strong Sell signal. It is a composite of Quality (28), Value (36), and Momentum (38) factor ranks across MoatMap’s 20,000+ stock universe.
Does Pliant Therapeutics, Inc. have an economic moat?
Pliant Therapeutics, Inc. (PLRX) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Pliant Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Pliant Therapeutics, Inc. (PLRX) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Pliant Therapeutics, Inc. in?
Pliant Therapeutics, Inc. (PLRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksPLRX deep dive reportAI ChampionsHow we score stocksSense-check another stock